Yet prescription rates remain substantially lower than that seen for other guideline-recommended cardiometabolic therapies Barriers for proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) use persist for cholesterol management, according to a research letter published online Feb. 16 in Circulation: Cardiovascular Quality and Outcomes. Diane E. MacDougall, from the Family Heart Foundation in Fernandina Beach, Florida, and...